MARKET

AMRX

AMRX

AMNEAL PHARMACEU
NYSE

Real-time Quotes | Nasdaq Last Sale

4.210
+0.110
+2.68%
After Hours: 4.280 +0.07 +1.66% 19:58 12/04 EST
OPEN
4.110
PREV CLOSE
4.100
HIGH
4.260
LOW
4.070
VOLUME
748.38K
TURNOVER
--
52 WEEK HIGH
5.79
52 WEEK LOW
2.400
MARKET CAP
1.26B
P/E (TTM)
10.29
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
5 Value Stocks To Watch In The Healthcare Sector
Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labeled as a value stock.The following stocks are considered to be notable value stocks in the healthcare sector: 1. Satsuma Pharmaceuticals (NASDAQ: STSA) - P/E: 2.34 2. Acorda Therapeutics (NASDAQ: ACOR) - P/E: 0.69 3. Biogen (NASDAQ: BIIB) - P/E: 8.05 4. Amneal Pharmaceuticals (NYSE: AMRX) - P/E: 9.13 5. Bio-Rad Laboratories (NYSE: BIO) - P/E: 4.88This quarter, Satsuma Pharmaceuticals experienced a decrease in earnings per share, which was -0.65 in Q2 and is now -0.69. Satsuma Pharmaceuticals does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Most recently, Acorda Therapeutics reported earnings per share at -0.23, whereas in Q2 earnings per share sat at -0.35. Acorda Therapeutics does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Biogen's earnings per share for Q3 sits at 8.84, whereas in Q2, they were at 10.26. Biogen does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Most recently, Amneal Pharmaceuticals reported earnings per share at 0.16, whereas in Q2 earnings per share sat at 0.13. Amneal Pharmaceuticals does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.This quarter, Bio-Rad Laboratories experienced an increase in earnings per share, which was 1.61 in Q2 and is now 3.0. Bio-Rad Laboratories does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.See more from Benzinga * Click here for options trades from Benzinga * Overview Of Value Stocks In The Real Estate Sector * A Preview Of Dick's Sporting Goods's Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga · 11/23 15:24
Is Amneal Pharmaceuticals (AMRX) a Good Stock to Pick Now?
Is Amneal Pharmaceuticals (AMRX) a great pick from the value investor's perspective right now? Read on to know more.
Zacks · 11/16 14:45
The Daily Biotech Pulse: Novartis Drug Flunks COVID-19 Study, Molecular Templates' Blood Cancer Study Placed On Partial Hold
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 5)
Benzinga · 11/06 12:47
Amneal Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 6, 2020 / Amneal Pharmaceuticals, Inc.
ACCESSWIRE · 11/06 11:30
Amneal Pharmaceuticals (AMRX) Reports Next Week: Wall Street Expects Earnings Growth
Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 10/30 17:30
Why Amneal (AMRX) is Poised to Beat Earnings Estimates Again
Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks · 10/22 17:10
Aclaris (ACRS) Begins Phase II Study on Eczema Candidate
Aclaris (ACRS) initiates a phase IIa study on ATI-1777, for the treatment of moderate-to-severe atopic dermatitis.
Zacks · 10/21 15:46
Is AMNEAL PHARMACEUTICALS, INC. (AMRX) Stock Outpacing Its Medical Peers This Year?
Is (AMRX) Outperforming Other Medical Stocks This Year?
Zacks · 10/20 16:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AMRX. Analyze the recent business situations of AMNEAL PHARMACEU through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 12 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AMRX stock price target is 4.444 with a high estimate of 6.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 224
Institutional Holdings: 127.10M
% Owned: 42.40%
Shares Outstanding: 299.75M
TypeInstitutionsShares
Increased
37
4.56M
New
34
138.26K
Decreased
49
4.95M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.23%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/Independent Director
Paul Meister
President/Co-Chief Executive Officer/Director
Chirag Patel
Co-Chief Executive Officer/Co-Founder/Director
Chintu Patel
Chief Financial Officer/Senior Vice President
Anastasios Konidaris
Corporate Executive
Sanjay Jain
Chief Human Resource Officer/Senior Vice President
Nikita Shah
Executive Vice President
Andrew Boyer
Senior Vice President/General Counsel/Secretary
Stephen Manzano
Executive Vice President/Chief Scientific Officer
Shankar Hariharan
Senior Vice President
Joseph Greer
Senior Vice President
Apurva Saraf
Senior Vice President
Joseph Todisco
Director
Gautam Patel
Independent Director
Emily Alva
Independent Director
J. Kevin Buchi
Independent Director
Jeffrey George
Independent Director
John Kiely
Independent Director
Ted Nark
Independent Director
Shlomo Yanai
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AMRX
Amneal Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. It operates in two segments, which include Generics and Specialty Pharma. The Generics is focused on the development, manufacture, sale and distribution of the Company's generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their drug names. The Specialty Pharma is engaged in the promotion, sale and distribution of several branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson's disease (PD), post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Amneal Pharmaceuticals Inc stock information, including NYSE:AMRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AMRX stock methods without spending real money on the virtual paper trading platform.